Lantheus Holdings, Inc. (LNTH) to Release Earnings on Monday
Lantheus Holdings, Inc. (NASDAQ:LNTH) will be posting its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Lantheus Holdings to post earnings of $0.21 per share for the quarter.
Lantheus Holdings (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.18. The business had revenue of $88.83 million for the quarter, compared to analysts’ expectations of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.24 EPS. On average, analysts expect Lantheus Holdings to post $1.12 EPS for the current fiscal year and $1.15 EPS for the next fiscal year.
Shares of Lantheus Holdings, Inc. (LNTH) traded up 0.137% during mid-day trading on Monday, hitting $18.275. The stock had a trading volume of 17,687 shares. The stock has a market cap of $682.57 million, a P/E ratio of 24.966 and a beta of 0.91. The firm has a 50 day moving average of $17.66 and a 200-day moving average of $17.66. Lantheus Holdings, Inc. has a one year low of $7.95 and a one year high of $20.45.
A number of research firms have weighed in on LNTH. Jefferies Group LLC reissued a “buy” rating and set a $22.00 price objective on shares of Lantheus Holdings in a research note on Thursday, October 12th. Zacks Investment Research lowered Lantheus Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. BidaskClub lowered Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Credit Suisse Group boosted their price objective on Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Cantor Fitzgerald began coverage on Lantheus Holdings in a research note on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.60.
In other Lantheus Holdings news, Director Derace L. Schaffer sold 15,000 shares of Lantheus Holdings stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $17.50, for a total value of $262,500.00. Following the sale, the director now owns 48,730 shares in the company, valued at $852,775. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John W. Crowley sold 6,755 shares of Lantheus Holdings stock in a transaction on Friday, October 13th. The shares were sold at an average price of $18.41, for a total value of $124,359.55. The disclosure for this sale can be found here. Insiders sold 903,099 shares of company stock worth $15,443,485 in the last 90 days. Company insiders own 2.30% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.